FDA’s 2025 user fee guidance updates small business fee waiver rules, detailing financial hardship criteria and replacing Forms 3602/3602A with Form 3602N. It supports small medical device companies by clarifying eligible documentation, including for entities in tax-exempt jurisdictions, to ease FDA registration costs and encourage market entry.
The FDA Medical Device User Fee Small Business Qualification and Determination Guidance 2025 provides critical updates for medical device companies seeking fee reductions or waivers under the Medical Device User Fee Amendments (MDUFA). This guidance clarifies eligibility criteria and the application process for small business status, which can reduce regulatory costs and streamline market access.
The FDA updated its guidance on July 31, 2025, superseding the 2018 version to reflect current fee structures and qualification criteria. Key changes include clearer definitions of “small business” based on gross receipts thresholds, and detailed instructions for domestic and foreign companies on how to apply for fee reductions or waivers.
This updated guidance provides clearer details on:
These changes aim to reduce administrative burdens and lower FDA costs for small medical device companies, including international firms, improving access to U.S. market pathways.
Qualifying as a small business can significantly reduce user fees associated with FDA submissions, such as 510(k)s, PMAs, De Novo requests, and establishment registrations. This reduces financial barriers for startups and smaller companies, encouraging innovation and faster patient access to new medical technologies.
For details on medical device classification and registration requirements, visit:
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us